A Roundup of Major Autoimmune Transactions in the First Half of 2025

A Roundup of Major Autoimmune Transactions in the First Half of 2025

Up to $13 billions! A Roundup of Major Autoimmune Transactions in the First Half of 2025.

Blog 2025-07-07

One receptor, two FDA-approved drugs — just how crucial is CXCR4?

In recent years, the successive approvals of two new drugs have once again brought a chemokine receptor into the spotlight. In 2023, the FDA approved Motixafortide (brand name Aphexda) in combination with long-acting G-CSF for hematopoietic stem cell mobilization in patients with multiple myeloma. Then in 2024, the FDA approved Mavorixafor (Xolremdi) for the treatment […]

Blog 2025-07-03

CCR1: An Emerging Target for Immune Regulation and Drug Development

CCR1 (C-C motif chemokine receptor 1) is a G protein-coupled receptor (GPCR) involved in inflammatory responses and immune cell migration. In recent years, with the deepening research on immune-related diseases and the tumor microenvironment, CCR1 has gradually emerged as an important therapeutic target for autoimmune diseases, tumors, and organ fibrosis. 1. Overview of CCR1 Chemokine monomers […]

Blog 2025-06-20

New Product Launch | DT3C Protein: A Powerful Tool for Validating Antibody Internalization

Are you developing antibody-drug conjugates (ADCs)? Are you seeking a reliable and standardized method to evaluate antibody internalization? We are proud to introduce the DT3C Protein (Cat. No. AME100004) — a novel recombinant fusion protein designed to simulate ADC mechanisms and provide a fast, universal, and functional solution for antibody internalization assessment. 1. What is […]

Uncategorized 2025-06-13

DIMA Membrane Proteins Empower Nobel Team’s Breakthrough in GPCR Drug Discovery

DIMA’s CXCR4-Nanodisc Empowers New Preprint from David Baker, which is entitled “De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors”

News 2025-05-26

FLT3 | A Key Therapeutic Target in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a complex and highly heterogeneous hematologic malignancy closely associated with various cytogenetic and chromosomal abnormalities. Among them, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are one of the most common genetic alterations. Studies have shown that approximately 25% of AML patients carry FLT3 internal tandem duplication mutations (FLT3-ITD), while about […]

Blog 2025-05-20

Dual-Payload ADCs: The Next Big Thing in the ADC Arena

Efforts to improve traditional ADCs have primarily focused on the three key components: the antibody, the linker, and the payload. Previously, we summarized the research progress in bispecific ADCs. Here, we further consolidate the pipeline updates of dual-payload ADCs.

Blog 2025-04-29

NPY Receptor Family: “New Targets” and “Old Challenges” in Disease Treatment

In the drug development efforts targeting complex diseases such as neuropsychiatric disorders, metabolic dysregulation, and cancer, the neuropeptide Y (NPY) receptor family is garnering increasing attention from researchers and pharmaceutical companies alike. As a typical subfamily of G protein-coupled receptors (GPCRs), NPY receptors not only regulate a variety of physiological processes but also play critical […]

Blog 2025-04-28

Popular Targets in the Bispecific ADC Pipeline

At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such as bispecific ADCs and dual-toxin ADCs, forming a unique landscape at the AACR meeting. Here, we summarize the key players and target pipelines in the bispecific ADC (BsADC) space, based on AACR data.

Blog 2025-04-25

An Invitation|Welcome to meet DIMA BIOTECH in Boston in May

DIMA BIOTECH will showcase over 5,000+ in-stock lead mAbs and 500+ in-stock Nanodisc at 2025 CAS and 2025 PEGS.

News 2025-04-25